These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10822766)

  • 21. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Spontaneous intestinal hematoma as anticoagulant treatment complication].
    Leonardo G; Catracchia V; Molina A; Bengochea JM; Heredero JM; Lòpez A; Gòmez O; Bezzi M
    G Chir; 2008 Oct; 29(10):421-3. PubMed ID: 18947465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acenocoumarol and vasculitis: a case report.
    Aouam K; Gassab A; Khorchani H; Bel Hadj Ali H; Amri M; Boughattas NA; Zili JE
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):113-4. PubMed ID: 16981216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upper airway obstruction by sublingual hematoma: a complication of anticoagulation therapy with acenocoumarol.
    González-García R; Schoendorff G; Muñoz-Guerra MF; Rodríguez-Campo FJ; Naval-Gías L; Sastre-Pérez J
    Am J Otolaryngol; 2006; 27(2):129-32. PubMed ID: 16500477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Toxicodermia complicated by disseminated intravascular coagulation syndrome].
    Milevskaia SG; Novitskiĭ BV
    Vestn Dermatol Venerol; 1983 Nov; (11):65-7. PubMed ID: 6230815
    [No Abstract]   [Full Text] [Related]  

  • 27. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
    de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
    Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The blue toe syndrome during oral anticoagulant therapy with acenocoumarol.
    Fernández MA; Andreu R; Fortea JM; Aznar J
    Thromb Haemost; 2001 Apr; 85(4):743. PubMed ID: 11341514
    [No Abstract]   [Full Text] [Related]  

  • 29. [Disseminated intravascular coagulation after oral ingestion of hydrochloric acid].
    Hüttel MS
    Ugeskr Laeger; 1980 Apr; 142(15):962-3. PubMed ID: 7385393
    [No Abstract]   [Full Text] [Related]  

  • 30. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.
    Jose L; Binila C; Chandy SJ; Mathews JE; Mathews KP
    J Assoc Physicians India; 2008 Apr; 56():250-2. PubMed ID: 18702389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Safety of aspirin, clopidogrel, and acenocumarol combination in patients requiring anticoagulation].
    Sánchez-Torrijos J; Gudín-Uriel M; Ridocci-Soriano F
    Rev Esp Cardiol; 2006 Dec; 59(12):1345-6. PubMed ID: 17194433
    [No Abstract]   [Full Text] [Related]  

  • 32. Clofibrate-induced myocardial injury and disseminated intravascular coagulation in a patient with chronic renal failure.
    Scionti L; Calafiore R; Coaccioli S; Bellomo G; Berrettini M; Puxeddu A
    Panminerva Med; 1984; 26(1):45-7. PubMed ID: 6728507
    [No Abstract]   [Full Text] [Related]  

  • 33. Delayed Allergic Reaction to Acenocoumarol With a Positive Lymphocyte Transformation Test.
    Dominguez-Ortega J; Entrala A; Pola-Bibian B; Gonzalez-Muñoz M; Fiandor A; Quirce S
    J Investig Allergol Clin Immunol; 2016; 26(4):273-4. PubMed ID: 27470649
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypervitaminosis E.
    Moharana S; Moharana DN
    Indian J Physiol Pharmacol; 1999 Jul; 43(3):407-9. PubMed ID: 10776496
    [No Abstract]   [Full Text] [Related]  

  • 35. Activated recombinant factor VII to reverse oral anticoagulants for emergent cesarean delivery.
    Morante L; Guasch EV; Palacio F; Gilsanz F
    Anesth Analg; 2006 Jun; 102(6):1902-3. PubMed ID: 16717350
    [No Abstract]   [Full Text] [Related]  

  • 36. [Secondary drug toxiderma to acenocoumarol].
    Khammassi N; Kessentini N
    Pan Afr Med J; 2015; 22():95. PubMed ID: 26848342
    [No Abstract]   [Full Text] [Related]  

  • 37. [Syncumar necrosis and phlagmasia coerulea dolens as a complication of bronchial cancer].
    Petö I; Bajtai A; Sas G; Juhász J
    Orv Hetil; 1982 Sep; 123(37):2299-301. PubMed ID: 7145396
    [No Abstract]   [Full Text] [Related]  

  • 38. [Thrombopenia and intravascular coagulation during heparin treatment].
    Roussi J; Bor Y; Dechy H; Houbouyan L; Dorra M
    Nouv Presse Med; 1982 Jan; 11(2):132-3. PubMed ID: 7058132
    [No Abstract]   [Full Text] [Related]  

  • 39. [Laser in the management of syncumar necrosis].
    Mester E
    Orv Hetil; 1981 Aug; 122(32):1995. PubMed ID: 7301366
    [No Abstract]   [Full Text] [Related]  

  • 40. [Patient with haemoptysis, dyspnoea, fever and lung infiltration].
    Zielińska-Leś I; Kozielski J; Kamiński J
    Wiad Lek; 2006; 59(3-4):289-91. PubMed ID: 16813283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.